Search for: [Abstract = "The aim of the study was assessment of the efficacy of the standard vaccination against HBV among HIV infected patients and vaccination with additional doses in patients who did not develop the protective level of antibody after the initial vaccination. Analysis of the influence on the vaccination such factors like\: stage of HIV infection, antiretroviral therapy, age and patient’s sex and co\-infection with HCV has been done. The impact of the vaccination on the course of HIV has been assessed. Protective level of anti\-HBs antibodies after the primary vaccination course was found in 92,9% persons of control group and only in 63% of HIV infected individuals. Anti\-HBs above 100 IU\/l was twice more common in control group \(80,4%\) than in HIV infected \(46,3%\) and differences were statistically significant \(p < 0,001\). Only 14,3% of patients with CD4 cell count below 200 cells\/µl developed protective level of anti\-HBs, none of them had anti\-HBs above 100 IU\/l, whereas patients with higher CD4 cells count responded better for vaccination \(p = 0,015\). Protective level of anti\-HBs was a little bit more common among persons with viral load lower than 10 000 copies\/ml \(64,6%\) in comparison with group of patients with higher viral load \(50%\). The CD4 cells count and viral load in the past \(CD4min, HIV\-RNAmax\) did not have impact on the vaccination efficacy, but the worst response was obser"]

Number of results: 1